β-Cell regeneration mediated by human bone marrow mesenchymal stem cells

Area of Science:

• * Regenerative Medicine
• * Stem Cell Biology
• * Endocrinology

Background:

• * Bone marrow mesenchymal stem cells (BMSCs) show therapeutic potential for diabetes in animal models.
• * The precise mechanisms underlying BMSC efficacy in diabetes remain largely unelucidated.
• * Key questions involve BMSC differentiation into beta-cells or their role in endogenous beta-cell recovery.

Purpose of the Study:

• * To investigate the therapeutic potential of human BMSCs (hBMSCs) genetically modified to express vascular endothelial growth factor (VEGF) or pancreatic-duodenal homeobox 1 (PDX1) in a mouse model of diabetes.
• * To determine if these modified hBMSCs differentiate into functional beta-cells or promote recovery through alternative pathways.
• * To elucidate the mechanisms by which hBMSCs mediate diabetes reversal.

Main Methods:

• * Genetic modification of human BMSCs to express VEGF or PDX1.
• * Transplantation of modified hBMSCs into diabetic mouse models.
• * Assessment of glycemic control, survival, weight maintenance, and beta-cell regeneration.
• * Measurement of serum human insulin levels and analysis of insulin/IGF receptor signaling pathways.

Main Results:

• * Both hBMSC-VEGF and hBMSC-PDX1 treatments reversed hyperglycemia in over 50% of diabetic mice.
• * All treated mice showed improved survival and weight maintenance.
• * Sustained diabetes reversal was observed exclusively in mice treated with hBMSC-VEGF.
• * De novo beta-cell differentiation from human cells was confirmed in both treatment groups.
• * Sustained recovery with hBMSC-VEGF was linked to endogenous beta-cell regeneration and activation of the insulin/IGF receptor pathway.

Conclusions:

• * Genetically modified hBMSCs hold therapeutic potential for insulin-dependent diabetes.
• * VEGF-modified hBMSCs can induce sustained diabetes remission through endogenous beta-cell regeneration.
• * The findings provide novel insights into the mechanisms of beta-cell recovery mediated by hBMSC therapy.